12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PF-05280586: Phase I/II started

In March, Pfizer began the double-blind, international Phase I/II REFLECTIONS B328-01 trial to compare PF-05280586 vs. Rituxan/ MabThera rituximab in 210 patients who had an inadequate response to tumor necrosis factor (TNF) therapy. Patients will continue methotrexate throughout the study and will receive 1,000 mg IV PF-05280586, Rituxan or MabThera given on days 1 and 15. Pfizer told BioCentury that the trial...

Read the full 311 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >